Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Jay Sussman

Nuclear Cardiology Moorestown, NJ Medical Doctor

NPI 1851368062 CMS profile 219756

401 Young Ave, Suite 275, Moorestown, NJ 08057

Open in the dashboard

General payments

$3,105

176 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Jay Sussman of Moorestown, NJ is reported in the CMS Open Payments database as having received $3,105 across 176 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Nuclear Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $47 3
2023 General $59 3
2022 General $377 25
2021 General $497 17
2020 General $518 28
2019 General $1,608 100

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jay Sussman
  • Nuclear Cardiology median
  • Middle half of Nuclear Cardiology
  • National median

In program year 2025, general payments to Jay Sussman were reported at $0. Among 99 Nuclear Cardiology profiles paid that year, the median was $434 and the middle half received between $138 and $985.

Show as a table
Year Jay Sussman Nuclear Cardiology median Middle half National median
2019 $1,608 $552 $91–$1,768 $163
2020 $518 $204 $61–$1,106 $114
2021 $497 $354 $99–$886 $132
2022 $377 $506 $101–$1,186 $149
2023 $59 $545 $148–$1,432 $160
2024 $47 $484 $131–$1,430 $164
2025 $0 $434 $138–$985 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Boston Scientific Corporation $798 23 payments
  2. Amgen Inc. $497 34 payments
  3. Amarin Pharma Inc. $284 13 payments
  4. Pfizer Inc. $283 17 payments
  5. Janssen Pharmaceuticals, Inc $234 21 payments
  6. AstraZeneca Pharmaceuticals LP $189 8 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $175 14 payments
  8. Novartis Pharmaceuticals Corporation $124 9 payments
  9. Philips Electronics North America Corporation $102 6 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $80 6 payments
  11. Other $340 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $3,105 176 payments
Products named General payments · program years 2019–2024
  1. Repatha $497 34 payments
  2. ELIQUIS $283 17 payments
  3. Corlanor $266 18 payments
  4. WATCHMAN $262 15 payments
  5. XARELTO $234 21 payments
  6. LUX DX $209 2 payments
  7. Vascepa $186 6 payments
  8. EMBLEM $176 2 payments
  9. LifeVest $175 14 payments
  10. ENTRESTO $124 9 payments
  11. Other $1,183 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

176 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nuclear Cardiology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record